目的 觀察燈盞生脈膠囊聯(lián)合單硝酸異山梨酯治療冠心病心絞痛的臨床療效。方法 選取2015年8月—2017年6月在北京市東城區(qū)第一人民醫(yī)院內科確診的84例冠心病心絞痛患者，將研究對象隨機分為對照組和治療組，每組各42例。對照組泵入單硝酸異山梨酯注射液，60 mg/次，1次/d，10 d后轉為口服單硝酸異山梨酯片，20 mg/次，2次/d。治療組在對照組的治療基礎上口服燈盞生脈膠囊，2粒/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效和心電圖療效，比較兩組治療前后心絞痛發(fā)作頻率、持續(xù)時間、血脂四項、超敏C-反應蛋白（hs-CRP）、纖維蛋白原（FIB）、D-二聚體的變化情況。結果 治療后，對照組和治療組的臨床總有效率分別為76.19%、92.86%；心電圖總有效率分別為71.43%、88.10%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作頻率較治療前明顯減少，持續(xù)時間的較治療前明顯縮短，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療后，治療組心絞痛發(fā)作頻率少于對照組，每次的持續(xù)時間短于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）均低于治療前，但高密度脂蛋白（HDL-C）高于治療前，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療后，治療組TC、TG、LDL-C低于對照組，HDL-C高于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，對照組患者hs-CRP降低，治療組hs-CRP、FIB、D-二聚體水平較治療前顯著降低，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療后，治療組hs-CRP、FIB、D-二聚體低于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。結論 燈盞生脈膠囊聯(lián)合單硝酸異山梨酯治療冠心病心絞痛具有較好的臨床療效，可顯著改善癥狀，降低炎癥指標，具有一定的臨床推廣應用價值。

Objective To observe the clinical curative effect of Dengzhan Shengmai Capsules combined with isosorbide mononitrate in treatment of coronary heart disease with angina pectoris. Methods Patients (84 cases) with coronary heart disease with angina pectoris in Department of Internal Medicine in the First People's Hospital of Dongcheng District in Beijing from August 2015 to June 2017 were randomly divided into control (42 cases) and treatment (42 cases) groups. Patients in the control group were iv administered with Isosorbide Mononitrate Injection, 60 mg/time, once daily. After 10 d, they were po administered with Isosorbide Mononitrate Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy and electrocardiogram effect was evaluated, and the changes of angina pectoris frequency and duration, blood lipids, hs-CRP, FIB, and D-dimer in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 76.19% and 92.86%, respectively, and electrocardiogram efficacy were 71.43% and 88.10%, respectively, there was difference between two groups (P < 0.05). After treatment, angina pectoris frequency in two groups was decreased, and duration time was shorted, and the difference was statistically significant in the same group (P < 0.05). After treatment, angina pectoris frequency was less than that in the control group, and duration time was shorted than that in the control group, and there was difference between two groups (P < 0.05). After treatment, TC, TG, and LDL-C in two groups were decreased, but HDL-C was increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, TC, TG, and LDL-C in treatment group were lower than those in the control group, but HDL-C was higher than that in the control group, there was difference between two groups (P < 0.05). After treatment, hs-CRP in the control group was decrease, and hs-CRP, FIB, and D-dimer in the treatment group were decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, hs-CRP, FIB, and D-dimer in the treatment group were lower than those in the control group, there was difference between two groups (P < 0.05). Conclusion Dengzhan Shengmai Capsules combined with isosorbide mononitrate has clinical curative effect in treatment of coronary heart disease with angina pectoris, and can significantly improve symptoms, also can reduce inflammatory indicators, which has a certain clinical application value.